First Trust Nasdaq Pharmaceuticals ETF
FTXH
20 hedge funds and large institutions have $6.79M invested in First Trust Nasdaq Pharmaceuticals ETF in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
17% more capital invested
Capital invested by funds: $5.78M → $6.79M (+$1.01M)
6.01% more ownership
Funds ownership: 38.88% → 44.89% (+6%)
5% less funds holding
Funds holding: 21 → 20 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$1.36M |
| 2 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$436K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$220K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$73.7K |
| 5 |
VCM
Vivaldi Capital Management
Chicago,
Illinois
|
+$67.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.28M |
| 2 |
SPIA
Steward Partners Investment Advisory
New York
|
-$134K |
| 3 |
LFG
Larson Financial Group
St Louis,
Missouri
|
-$19.2K |
| 4 |
CA
Continuum Advisory
Eagle,
Idaho
|
-$17.5K |
| 5 |
WFA
WMG Financial Advisors
Knoxville,
Tennessee
|
-$11K |
FTXH Hedge Fund Activity: Q1 2025 in Review
20 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q1 2025, worth a combined $6.79M — up 17% from $5.78M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of FTXH and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 9 added.
The largest buyer was LPL Financial, adding an estimated $1.36M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $1.28M sold.
- 20 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q1 2025, down from 21 in Q4 2024.
- Funds reported $6.79M of First Trust Nasdaq Pharmaceuticals ETF stock for Q1 2025, up 17% quarter-over-quarter.
- 2 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q1 2025 and 3 closed out, a net change of -1 holder.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q1 2025 was LPL Financial, an estimated $1.36M added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q1 2025 was Susquehanna International Group, an estimated $1.28M sold.
Based on aggregated 13F filings for Q1 2025.